Diagnostic value of CA125 as a predictor of recurrence in advanced ovarian cancer

Purpose: The aim of this study was to establish the guidelines for detecting early recurrences of advanced epithelial ovarian cancer by use of the CA-125 level. Materials and Methods: Eighty-five of the patients who met the inclusion criteria were enrolled in this study. The authors examined 25 incremental changes of CA125 from one to 25 IU/ml, and compared the CA-125 value with other prognostic factors. Increases in the CA-125 level from the nadir level were expressed as CA-125- increments. Results: Among the 25 increments, a CA-125-8 (eight IU/ml) was selected as the predictor that was the most efficient and time-effective. CA-125-8 had a sensitivity of 91.5%, a specificity of 84.6%, a positive predictive value of 93.1%, a negative predictive value of 81.5%, an efficiency of 89.4%. and a median lead-time of 68.5 days (p < 0.0001). Conclusion: The authors suggest the incremented CA-125-8 as a predictor of recurrent advanced ovarian cancer.

Advanced ovarian cancer, CA-125; Early detection of recurrence.

[1] Rustin G.J., Bast R.C. Jr., Kelloff G.J., Barrett J.C., Carter S.K., Nisen P.D. et al.: “Use of CA125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer”. Clin. Cancer Res., 2004, 10, 3919.

[2] Ozols R.F., Bundy B.N., Greer B.E., Fowler J.M., Clarke-Pearson D., Burger R.A. et al.: “Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected Stage III ovarian cancer: a Gynecologic Oncology Group study”. J. Clin. Oncol., 2003, 21, 3194.

[3] Mano M.S., Awada A., Minisini A., Atalay G., Lago L.D., Cardoso F. et al.: “Remaining controversies in the upfront management of advanced ovarian cancer”. Int. J. Gynecol. Cancer, 2004, 14, 707.

[4] Schorge J.O.: “From epithelial ovarian cancer: gynecologic oncology”. In: Williams Gynecology. 1st ed. Edited by Schorge J.O., Schaffer J.I., Halvorson L.M., Hoffman B.L., Bradshaw K.D. and Cunningham F.G. Dallas, TX: The McGraw-Hill Companies, Inc.; 2008, 716.

[5] Rustin G.J., van der Burg M.E., Griffin C.L., Guthrie D., Lamont A., Jayson G.C. et al.: “Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial”. Lancet, 2010, 376, 1155.

[6] Zang R.Y., Li Z.T., Tang J., Cheng X., Cai S.M., Zhang Z.Y. et al.: “Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits?”. Cancer, 2004, 100, 1152.

[7] Chi D.S., McCaughty K., Diaz J.P., Huh J., Schwabenbauer S., Hummer A.J. et al.: “Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma”. Cancer, 2006, 106, 1933.

[8] Harter P., du Bois A., Hahmann M., Hasenburg A., Burges A., Loibl S. et al.: “Surgery in recurrent ovarian cancer: The Arbeitsgemeinschaft Gynaekologische Onkologie(AGO) DESKTOPOVARTrial”. Ann. Surg. Oncol., 2006, 13, 1702.

[9] Salani R., Santillan A., Zahurak M.L., Giuntoli R.L. 2nd, Gardner G.J., Armstrong D.K. et al.: “Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome”. Cancer, 2007, 109, 685.

[10] Santillan A., Karam A.K., Li A.J., Giuntoli R. 2nd, Gardner G.J., Cass I. et al.: “Secondary cytoreductive surgery for isolated nodal recurrence in patients with epithelial ovarian cancer”. Gynecol. Oncol., 2007, 104, 686.

[11] Goonewardene T.I., Hall M.R., Rustin G.J.: “Management of asymptomatic patients on follow-up for ovarian cancer with rising CA125 concentrations”. Lancet Oncol., 2007, 8, 813.

[12] Tuxen M.K., Sölétormos G., Dombernowsky P.: “Serum tumor marker CA125 for monitoring ovarian cancer during follow-up”. Scand. J. Clin. Lab. Invest., 2002, 62, 177.

[13] Duffy M.J., Bonfrer J.M., Kulpa J., Rustin G.J., Soletormos G., Torre G.C. et al.: “CA125 in ovarian cancer: European group on tumor markers guidelines for clinical use”. Int. J. Gynecol. Cancer, 2005, 15, 679.

[14] Rustin G.J.: “Use of CA125 to assess response to new agents in ovarian cancer trials”. J. Clin. Oncol., 2003, 21, 187.

[15] Rustin G.J., Nelstrop A.E., Tuxen M.K., Lambert H.E.: “Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study”. Ann. Oncol., 1996, 7, 361.

[16] Krebs H.B., Goplerud D.R., Kilpatrick S.J., Myers M.B., Hunt A.: “The role of CA 125 as tumour marker in ovarian cancer”. Obstet. Gynecol., 1986, 67, 473.

[17] Gronlund B., Lundvall L., Christensen I.J., Knudsen J.B., Høgdall C.: “Surgical cytoreduction in recurrent ovarian carcinoma in patients with complete response to paclitaxel-platinum”. Eur. J. Surg. Oncol., 2005, 31, 67.

[18] Simcock B., Neesham D., Quinn M., Drummond E., Milner A., Hicks R.J.: “The impact of PET/CT in the management of recurrent ovarian cancer”. Gynecol. Oncol., 2006, 103, 271.

[19] Crawford S.M., Peace J.: “Does the nadir CA125 concentration predict a long-term outcome after chemotherapy for carcinoma of the ovary?”. Ann. Oncol., 2005, 16, 47.

[20] Tuxen M.K., Sölétormos G., Dombernowsky P.: “Serum tumor marker CA125 in monitoring of ovarian cancer during first-line chemotherapy”. Br. J. Cancer, 2001, 84, 1301.

[21] Santillan A., Garg R., Zahurak M.L., Gardner G.J., Giuntoli R.L. 2nd, Armstrong D.K., Bristow R.E.: “Risk of epithelial ovarian cancer recurrence in patients with rising serum CA125 levels within the normal range”. J. Clin. Oncol., 2005, 23, 9338.

[22] Prat A., Parera M., Adamo B., Peralta S., Perez-Benavente M.A., Garcia A. et al.: “Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA125 levels”. Ann. Oncol., 2009, 20, 294.